Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS).

Sojung HanJi Yeon LimKyungjoo ChoHye-Won Lee Jun Yong Park Simon Weonsang Ro Kyung Sik KimHaeng Ran SeoDo Young Kim

Published in: Cancers (2022)

Targeting YAP/TAZ inhibition using the novel YAP1 inhibitor CA3 could be a promising therapeutic strategy to enhance sensitivity to sorafenib especially in HCCs with high YAP/TAZ expression in MCTS.

Keyphrases

poor prognosis
protein kinase
cancer therapy
long non coding rna
drug delivery